Compare AbCellera Biologics Inc (ABCL) vs Bitdeer Technologies Group (BTDR) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

BTDR trades at $14.25, up 2.89% today, with a bullish technical signal despite recent earnings misses. The company reported Q1 2026 revenue growth of 170% year-over-year to $188.9 million but posted a net loss. Analyst consensus is strongly bullish with an 81.82% buy rating and a $23.40 price target, suggesting significant upside. Recent developments include expansion into AI cloud infrastructure and new data center agreements in Norway and Canada.

The outlook for BTDR is mixed, with strong revenue growth and strategic AI expansion offset by persistent net losses and negative profit margins. Key risks include execution challenges in new ventures and sensitivity to Bitcoin market volatility. The stock presents a high-risk, high-reward opportunity, supported by Wall Street optimism but requiring careful monitoring of profitability trends.